AstraZeneca's (AZN) trial of its cholesterol treatment Crestor in patients on kidney dialysis...

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

AstraZeneca's (AZN) trial of its cholesterol treatment Crestor in patients on kidney dialysis has failed, Bernstein's Tim Anderson surmises. Pharma firms are shopping for new patients - like those with severe kidney disease - for their drugs, and "the outer limits of who might benefit next may have been reached," he writes. AZN -3.8%.